Nemotan (Nimodipine)

Nimodipine, the active ingredient in Nemotan, is a calcium channel blocker (dihydropyridine) presented as an oral dosage form for oral use. It is employed to prevent cerebral vasospasm following subarachnoid hemorrhage in adult patients. GNH USA supplies Nemotan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Nimodipine is used in the management of cerebrovascular complications related to subarachnoid hemorrhage, acting on the cerebral arterial circulation. - Cerebral vasospasm after subarachnoid hemorrhage: reduces the incidence of delayed ischemic neurological deficits. - Aneurysmal subarachnoid hemorrhage: improves cerebral blood flow and oxygen delivery. - Post‑hemorrhagic cerebral ischemia risk: helps maintain adequate perfusion pressure in the acute phase.

Nimodipine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity. - Dizziness or light‑headedness, especially when standing quickly. - Nausea or gastrointestinal discomfort. - Flushing or warmth sensation. - Hypotension: transient drop in blood pressure.

Serious or Rare Side Effects: - Severe hypotension or syncope. - Cardiac arrhythmias. - Hepatic dysfunction indicated by elevated liver enzymes. - Allergic reactions such as rash, pruritus, or angioedema.

Before initiating Nimodipine therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications. - Cardiovascular status: assess baseline blood pressure and heart rate. - Hepatic function: consider liver enzyme testing in patients with known liver disease. - Concomitant vasodilators: monitor for additive hypotensive effects. - Elderly patients: start at the lowest effective dose and observe tolerance. - Storage: Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Nimodipine can interact with several drug classes, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase Nimodipine plasma levels and risk of toxicity. - Concurrent use with other potent vasodilators: can cause profound hypotension.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Beta‑blockers: may mask tachycardia associated with hypotension. - Diuretics: may enhance orthostatic blood pressure drops.